What are Theravance Biopharma's profit margins?

Theravance Biopharma (TBPH) runs a 60.8% gross margin and a 1.2% operating margin, with a 104.3% net margin.

Where do Theravance Biopharma's ratios come from?

Every ratio is computed from Theravance Biopharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

Theravance Biopharma TBPH Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Profitability
Operating margin	1.2%+4.6pp	-3.4%+37.5pp	-40.9%+7.3pp	-48.2%+28.7pp	-76.9%-4.0pp
Net margin	104.3%+5.8pp	98.5%+62.0pp	36.5%+19.7pp	16.9%+106pp	-89.4%-1.7pp
Returns
Return on equity	50.2%+5.3pp	44.8%+30.8pp	14%+7.8pp	6.2%+37.7pp	-31.5%-2.4pp
Efficiency
Asset turnover	0.3×0.0×	0.3×0.0×	0.2×0.0×	0.2×0.0×	0.2×0.0×
Liquidity
Current ratio	13.1×+2.2×	10.9×+1.4×	9.5×+2.8×	6.7×+1.9×	4.8×-0.3×
Leverage
Debt-to-equity	0.1×0.0×	0.1×0.0×	0.2×0.0×	0.2×-0.1×	0.3×0.0×
Per Share
Book value per share	$5.67-1.6%	$5.76+28.5%	$4.48+1.1%	$4.43+32.7%	$3.34-7.1%
Valuation
Market capitalization	$890.32M+68.7%	$948.08M+28.9%	$735.27M+37.8%	$533.51M+20.8%	$441.77M-4.5%
Price / earnings	7.8×—	——	——	——	——
Price / sales	8.1×0.0×	8.8×-0.3×	9.2×+2.2×	6.9×+0.1×	6.8×-0.4×
Price / book	3.1×-0.1×	3.2×0.0×	3.2×+0.8×	2.4×-0.3×	2.7×0.0×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Theravance Biopharma.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Theravance Biopharma's profit margins?: Theravance Biopharma (TBPH) runs a 60.8% gross margin and a 1.2% operating margin, with a 104.3% net margin.
Where do Theravance Biopharma's ratios come from?: Every ratio is computed from Theravance Biopharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.